effect of venlafaxine on quality of life and acute pain induced by oxaliplatin

Evaluation of the effect of venlafaxine on quality of life and acute pain induced by oxaliplatin in cancer patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160920029889N6

Enrollment

Registered

2025-01-23

Start date

2024-12-10

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Gastrointestinal Cancer. Condition 2: Gastrointestinal Cancer. Malignant neoplasm of duodenum Malignant neoplasm of cecum

Interventions

Intervention 1: Intervention group: the group receiving venlafaxine 37.5 mg a day, 1 tablet after a meal, Actoverco company with the brand name Alventa Start time: the first day of chemot

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >18 years ALP, AST, ALT 150,000 and WBC > 4,000 receiving chemotherapy regimen containing oxaliplatin (FOLFOX) Absence of peripheral neuropathy at the beginning of the study

Exclusion criteria

Exclusion criteria: Having uncontrolled blood pressure Taking monoamine oxidase inhibitor (MAO-I) drugs at the same time or with an interval of 2 weeks Patients receiving linezolid antibiotic Patients receiving SSRI and SNRI drugs Presence of peripheral neuropathy with other causes (diabetes, thyroid dysfunction, seizure disorder, vitamin B12 deficiency, alcohol abuse and previous history of chemotherapy, etc.) Patients receiving other medications that reduce neuropathy symptoms: antidepressants, anticonvulsants, vitamin (E), glutamine, gabapentin, duloxetine, carbamazepine, phenytoin, valproic acid, lamotrigine, capsaicin cream, lidocaine gel or skin patch, amifostine External factors affecting the quality of life such as the death of first-degree relatives, dismissal from the work environment, unexpected accidents and change of residence.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale for pain questionnaire score. Timepoint: Before receiving the first cycle of chemotherapy, then every month. Method of measurement: Visual analogue scale for pain questionnaire score.;EORTC-QLQ questionnaire score C30. Timepoint: Visual analogue scale for pain questionnaire score. Method of measurement: EORTC-QLQ questionnaire score C30.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Shiva

Oroumia University of Medical Sciences

afshin.shiva@gmail.com+98 44 3275 4991

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026